AbbVie (4AB) Stock Forecast & Price Target

Compare

26 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4AB Analyst Ratings

Moderate Buy

15 Buy

7 Hold

0 Sell

Based on 22 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4AB Stock 12 Month Forecast

Average Price Target

€214.01

▲(9.41% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is €214.01 with a high forecast of €245.22 and a low forecast of €184.98. The average price target represents a 9.41% change from the last price of €195.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"158":"€158","180":"€180","202":"€202","224":"€224","246":"€246"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":245.22219619,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€245.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":214.0051560591,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€214.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":184.97729678,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€184.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[158,180,202,224,246],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,193.4,197.38632278384617,201.3726455676923,205.35896835153846,209.34529113538463,213.3316139192308,217.31793670307692,221.3042594869231,225.29058227076922,229.27690505461538,233.26322783846155,237.2495506223077,241.23587340615384,{"y":245.22219619,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,193.4,194.98501200454615,196.57002400909232,198.15503601363847,199.7400480181846,201.32506002273078,202.91007202727693,204.49508403182307,206.0800960363692,207.66510804091538,209.25012004546153,210.83513205000767,212.42014405455384,{"y":214.0051560591,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,193.4,192.75209975230769,192.1041995046154,191.45629925692307,190.80839900923078,190.16049876153846,189.51259851384614,188.86469826615385,188.21679801846153,187.5688977707692,186.92099752307692,186.2730972753846,185.6251970276923,{"y":184.97729678,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":166.992,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.268,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.314,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.814,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.791,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.727,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.837,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.443,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.189,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.918,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.029,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€245.22

Average Price Target€214.01

Lowest Price Target€184.98

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Courtney Breen

Bernstein

Hold

―

Assigned

12/19/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Disc Medicine (NASDAQ: IRON) and BioMarin Pharmaceutical (NASDAQ: BMRN)

David Amsellem

Piper Sandler

€244.79

Buy

25.15%

Upside

Reiterated

12/18/25

Piper Sandler Sticks to Their Buy Rating for AbbVie (ABBV)

Gavin Clark-Gartner

Evercore ISI

€188.04→€197.36

Buy

0.90%

Upside

Reiterated

12/17/25

AbbVie (ABBV) Gets a Buy from Evercore ISI

Jason Gerberry

Bank of America Securities

€197.36

Hold

0.90%

Upside

Reiterated

12/15/25

AbbVie Hold Rating: Balancing Growth Opportunities with Valuation and Pipeline Challenges

Louise Chen

Scotiabank

€237.17

Buy

21.25%

Upside

Reiterated

12/15/25

AbbVie (ABBV) Receives a Buy from Scotiabank

Terence Flynn

Morgan Stanley

€221.07→€227.85

Buy

16.49%

Upside

Reiterated

12/12/25

AbbVie price target raised to $269 from $261 at Morgan StanleyAbbVie price target raised to $269 from $261 at Morgan Stanley

Mohit Bansal

Wells Fargo

€220.23

Buy

12.59%

Upside

Reiterated

12/10/25

LargeCap Biopharma Outlook—We Like It

Rajesh Kumar

HSBC

€190.58→€224.46

Buy

14.76%

Upside

Upgraded

12/10/25

AbbVie upgraded to Buy from Hold at HSBCAbbVie upgraded to Buy from Hold at HSBC

Luisa Hector

Berenberg Bank

€228.7

Buy

16.92%

Upside

Reiterated

11/25/25

AbbVie (ABBV) Gets a Buy from Berenberg Bank

Trung Huynh

UBS

€165.17→€186.35

Hold

-4.73%

Downside

Reiterated

11/07/25

AbbVie price target raised to $220 from $195 at UBSAbbVie price target raised to $220 from $195 at UBS

Elmar Kraus

DZ BANK AG

€200.75

Hold

2.63%

Upside

Downgraded

11/04/25

AbbVie downgraded to Hold from Buy at DZ BankAbbVie downgraded to Hold from Buy at DZ Bank

Evan Seigerman

BMO Capital

€203.29→€218.53

Buy

11.72%

Upside

Reiterated

11/03/25

AbbVie (ABBV) Receives a Buy from BMO Capital

Geoff Meacham

Citi

€203.29→€199.05

Hold

1.76%

Upside

Reiterated

11/03/25

AbbVie price target lowered to $235 from $240 at CitiAbbVie price target lowered to $235 from $240 at Citi

Chris Schott

J.P. Morgan

€211.76→€220.23

Buy

12.59%

Upside

Reiterated

11/03/25

AbbVie price target raised to $260 from $250 at JPMorganAbbVie price target raised to $260 from $250 at JPMorgan

Steve Scala

TD Cowen

€237.17

Buy

21.25%

Upside

Reiterated

10/31/25

TD Cowen Remains a Buy on AbbVie (ABBV)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Courtney Breen

Bernstein

Hold

―

Assigned

12/19/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Disc Medicine (NASDAQ: IRON) and BioMarin Pharmaceutical (NASDAQ: BMRN)

David Amsellem

Piper Sandler

€244.79

Buy

25.15%

Upside

Reiterated

12/18/25

Piper Sandler Sticks to Their Buy Rating for AbbVie (ABBV)

Gavin Clark-Gartner

Evercore ISI

€188.04→€197.36

Buy

0.90%

Upside

Reiterated

12/17/25

AbbVie (ABBV) Gets a Buy from Evercore ISI

Jason Gerberry

Bank of America Securities

€197.36

Hold

0.90%

Upside

Reiterated

12/15/25

AbbVie Hold Rating: Balancing Growth Opportunities with Valuation and Pipeline Challenges

Louise Chen

Scotiabank

€237.17

Buy

21.25%

Upside

Reiterated

12/15/25

AbbVie (ABBV) Receives a Buy from Scotiabank

Terence Flynn

Morgan Stanley

€221.07→€227.85

Buy

16.49%

Upside

Reiterated

12/12/25

AbbVie price target raised to $269 from $261 at Morgan StanleyAbbVie price target raised to $269 from $261 at Morgan Stanley

Mohit Bansal

Wells Fargo

€220.23

Buy

12.59%

Upside

Reiterated

12/10/25

LargeCap Biopharma Outlook—We Like It

Rajesh Kumar

HSBC

€190.58→€224.46

Buy

14.76%

Upside

Upgraded

12/10/25

AbbVie upgraded to Buy from Hold at HSBCAbbVie upgraded to Buy from Hold at HSBC

Luisa Hector

Berenberg Bank

€228.7

Buy

16.92%

Upside

Reiterated

11/25/25

AbbVie (ABBV) Gets a Buy from Berenberg Bank

Trung Huynh

UBS

€165.17→€186.35

Hold

-4.73%

Downside

Reiterated

11/07/25

AbbVie price target raised to $220 from $195 at UBSAbbVie price target raised to $220 from $195 at UBS

Elmar Kraus

DZ BANK AG

€200.75

Hold

2.63%

Upside

Downgraded

11/04/25

AbbVie downgraded to Hold from Buy at DZ BankAbbVie downgraded to Hold from Buy at DZ Bank

Evan Seigerman

BMO Capital

€203.29→€218.53

Buy

11.72%

Upside

Reiterated

11/03/25

AbbVie (ABBV) Receives a Buy from BMO Capital

Geoff Meacham

Citi

€203.29→€199.05

Hold

1.76%

Upside

Reiterated

11/03/25

AbbVie price target lowered to $235 from $240 at CitiAbbVie price target lowered to $235 from $240 at Citi

Chris Schott

J.P. Morgan

€211.76→€220.23

Buy

12.59%

Upside

Reiterated

11/03/25

AbbVie price target raised to $260 from $250 at JPMorganAbbVie price target raised to $260 from $250 at JPMorgan

Steve Scala

TD Cowen

€237.17

Buy

21.25%

Upside

Reiterated

10/31/25

TD Cowen Remains a Buy on AbbVie (ABBV)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month

xxx

Success Rate

15/22 ratings generated profit

Average Return

+2.80%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 68.18% of your transactions generating a profit, with an average return of +2.80% per trade.

3 Months

xxx

Success Rate

21/28 ratings generated profit

Average Return

+7.73%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.73% per trade.

1 Year

Evan SeigermanBMO Capital

Success Rate

18/18 ratings generated profit

Average Return

+20.13%

reiterated a buy rating 2 months ago

Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +20.13% per trade.

2 Years

xxx

Success Rate

33/33 ratings generated profit

Average Return

+30.10%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +30.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4AB Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4AB has received 32 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. 4AB average Analyst price target in the past 3 months is 214.01.

Each month's total comprises the sum of three months' worth of ratings.

4AB Financial Forecast

4AB Earnings Forecast

Next quarter’s earnings estimate for 4AB is €2.86 with a range of €2.81 to €3.00. The previous quarter’s EPS was €1.59. 4AB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.

4AB Sales Forecast

Next quarter’s sales forecast for 4AB is €13.98B with a range of €13.85B to €14.51B. The previous quarter’s sales results were €13.46B. 4AB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.

4AB Stock Forecast FAQ

What is DE:4AB’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbvie’s 12-month average price target is 214.01.

What is DE:4AB’s upside potential, based on the analysts’ average price target?

Abbvie has 9.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Abbvie a Buy, Sell or Hold?

Abbvie has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 7 hold ratings and 0 sell ratings.

What is Abbvie’s share price target?

The average share price target for Abbvie is 214.01. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €245.22 ,and the lowest forecast is €184.98. The average share price target represents 9.41% Increase from the current price of €195.6.

What do analysts say about Abbvie?

Abbvie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Abbvie?

To buy shares of DE:4AB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AbbVie (4AB) Stock Forecast & Price Target

4AB Analyst Ratings

4AB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

4AB Analyst Recommendation Trends

4AB Financial Forecast

4AB Earnings Forecast

4AB Sales Forecast

4AB Stock Forecast FAQ

Detailed List of Analyst Forecasts